Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of bosentan and how well it works
when given together with gemcitabine and nab-paclitaxel for the treatment of pancreatic
cancer that cannot be removed by surgery (unresectable). Bosentan may block the hormone
endothelin and prevent the growth and spread of pancreatic cancer. Drugs used in
chemotherapy, such as gemcitabine and nab-paclitaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving bosentan with chemotherapy (gemcitabine and
nab-paclitaxel) may work better in treating patients with pancreatic cancer compared to
chemotherapy alone.